Organisation paid for research Program year 2024 Source: CMS Open Payments

Colorado Allergy and Asthma Centers PC

Neither a doctor nor a teaching hospital

Research payments

$628,503

68 payments

Through program year 2024, Colorado Allergy and Asthma Centers PC is reported as receiving $628,503 in research payments, across 68 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $2,092 1
2022 Research $177,764 7
2021 Research $127,617 35
2020 Research $310,691 23
2019 Research $10,339 2

Breakdown

Who paid Research payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $389,327 9 payments
  2. Genzyme Corporation $162,501 36 payments
  3. Aimmune Therapeutics, Inc. $66,335 21 payments
  4. GlaxoSmithKline, LLC. $10,339 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis $197,146 2 payments
  2. A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) $162,501 36 payments
  3. A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy $86,500 1 payment
  4. A Multi-Center, Double-Blinded and Open-Label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab As Retreatment, Self-Administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies Cqge031c2302, Cqge03 $79,704 2 payments
  5. A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $63,999 18 payments
  6. A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of Csj117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. $23,719 2 payments
  7. A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $10,339 2 payments
  8. Arc008 $2,092 1 payment
  9. A Randomized, Subject- and Investigator- Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of Lou064 in Patients With Inadequately Controlled Asthma $1,366 1 payment
  10. A Two Treatment Epoch Randomized Placebo Controlled Multi Centered Parallel Group Study to Assess the Safety of Qaw039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma $893 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record